Showing results (1011-1020 of 5,723) with videos related to
Sort By:
Pageof 573
Medical Oncology (Northwood, London, England)|February 10, 1999
Non-secretory solitary plasmacytoma of the spleenM D Colović, G M Janković, R B Colović, et al.Medical Oncology (Northwood, London, England)|February 10, 1999
Metastatic small cell lung cancer causing biliary obstructionM Obara, H Satoh, Y T Yamashita, et al.Medical Oncology (Northwood, London, England)|January 8, 2008
Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemiaDoru T Alexandrescu, Peter H WiernikMedical Oncology (Northwood, London, England)|January 9, 2008
Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexaroteneCourtney D DiNardo, Bonnie Ky, Dan T Vogl, et al.Medical Oncology (Northwood, London, England)|February 19, 2008
Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesisDaniel Tesfa, Tobias Gelius, Birgitta Sander, et al.Medical Oncology (Northwood, London, England)|October 9, 2009
Loss of p16INK4, alone and with overexpression of osteopontin, correlates with survival of patients with spinal metastasis from hepatocellular carcinomaHua-jiang Chen, Jian-ru Xiao, Wen YuanMedical Oncology (Northwood, London, England)|October 16, 2009
Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinibFengsheng Chen, Xi Luo, Jinbiao Zhang, et al.Medical Oncology (Northwood, London, England)|October 10, 2009
Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathwayJun Yao, Cuijuan QianMedical Oncology (Northwood, London, England)|September 28, 2019
Mechanism of VIPR1 gene regulating human lung adenocarcinoma H1299 cellsLufeng Zhao, Zipu Yu, Baiqin ZhaoMedical Oncology (Northwood, London, England)|September 28, 2019
SOX4 is activated by C-MYC in prostate cancerHongyan Dong, Jing Hu, Lin Wang, et al.Pageof 573